A ngiogenesis is necessary for the vascularization of a tumor, providing essential nourishment for tumor growth, and the progression and metastasis of cancer cells. 1 Although tremendous efforts and resources have been dedicated to discovering angiogenesis inhibitors, very few candidates have been approved by FDA for therapeutic applications. Currently, Avastin (bevacizumab), a humanized monoclonal antibody, and Macugen (Pegaptanib), a pegylated oligonucleotide aptamer, both directed against vascular endothelial growth factor (VEGF) pathway, are two of the approved drugs for clinical use. There is still a great need to develop small molecule drugs for antiangiogenesis purpose. One approach to broaden the discovery platform is to identify antiangiogenic activities from existing drugs that have well defined toxicity and pharmacokinetics. Once a known drug is demonstrated to inhibit angiogenesis, it would move into the clinic trails more rapidly. Because most known drugs have well defined structures and defined biological targets, it is also possible to further improve the compound structure or select the target as a new entry point for angiogenesis-based studies and therapies. Currently there are more than 2000 known drugs that can be used for re-purposing applications. It would be desirable to have a single in vivo assay allowing rapid screening of a large number of compounds for new activities such as angiogenesis inhibition. Recently, the zebrafish has been shown to be a useful model organism for this type of approach. 2,3 Zebrafish blood vessels form by angiogenic sprouting and appear to use the same pathways necessary for blood vessel growth in mammals. 4 Using transgenic embryos expressing GFP in vessels, the embryonic blood vessels in live zebrafish can be directly visualized in multiwell plates for rapidly screening compounds affecting blood vessel formation and patterning. 5 This approach is highly effective and specific as was shown by the effect of previously known antiangiogenic compounds, such as SU6668 and SU5416, on embryonic blood vessel formation of zebrafish. 5 To identify clinically applicable drugs for antiangiogenesis we screened a library of 1120 compounds consisting of 85% FDA approved drugs (Prestwick Chemical, Inc) for inhibition of blood vessels. Live transgenic zebrafish embryos expressing GFP in vascular endothelial cells under the control of flk (also known as the VEGF receptor 2 gene) regulatory sequences were directly visualized under a fluorescent microscope to reveal drug-induced alteration of fluorescent blood vessels. 5 An initial screen of the drugs (at 10 mol/L concentration with 3 embryos in 200 L fish water per well of 96-well duplicate plates) identified several drugs that exhibited certain degree of inhibition of blood vessels but had no other detrimental effects on general embryonic development. Here we report one of the inhibitors, mycophenolic acid (MPA, Figure, A) , for its efficacy and the subsequent target validation studies.
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MPA is an immuno-suppressive drug that is widely used to prevent rejection of transplanted organs. 6, 7 Transgenic zebrafish embryos treated with 0.9 mol/L MPA significantly inhibited the sprouting of intersegmental blood vessels (ISV; Figure, B and C). We demonstrated that the circulation of these embryos was also blocked using microangiographic analysis ( Figure, 8, 9 Strengthening their discovery, our independent study established the action of MPA in vivo. Furthermore, because inosine monophosphate dehydrogenase (IMPDH) is known as the molecular target of MPA, 6, 7 we identified the target genes from zebrafish. Sequence alignment revealed that humans have 2 isoforms of IMPDH 10, 11 whereas the zebrafish genome contains 3, possibly because of additional gene duplications. 12 The amino acid sequences are highly conserved from human to zebrafish (more than 90% identity; see data supplement, available online at http://atvb.ahajournals. org). Expression analysis by RNA whole mount in situ hybridization of the 3 genes in zebrafish embryos showed that IMPDH 2 is mainly expressed in the ventral regions of the developing trunk (Figure, K) . This is where we used the ISVs as an angiogenic sprouting assays for new blood vessels. The other two IMPDH isoforms are expressed in the superficial epithelial cells that are distal to the ISVs (Figure, L and M) .
To study function of IMPDH in angiogenesis, antisense morpholino (MO) oligos against the translational sites of mRNA encoding the IMPDH1b and IMPDH2 were synthesized and injected in the flk-GFP transgenic embryos. As expected we did not observe any effect of IMPDH1b MO on angiogenesis (data not shown). However, injection of IM-PDH2 MO (5 ng MO per embryo) significantly inhibited angiogenesis in zebrafish (nϾ200, Ͼ50% showed phenotype whereas MO for IMPDH1b showed less than 2%, serving as a negative control for MO injection; see supplementary data). The phenotypes induced by MPA treatment and IMPDH2 knockdown appear indistinguishable (Figure, C and F ). In addition, we observed a synergistic action between IMPDH2-MO knockdown and treatment with MPA. Nearly complete inhibition of ISV sprouting could be achieved by applying combination of 20% of the normal amount of IMPDH2-MO and MPA concentrations that are individually required to have an effect on inhibiting angiogenesis in zebrafish embryos. As an internal control, we analyzed vascular structures in the head region. We noticed that all major vessels were present in the head, although ISVs in the same embryos were blocked by MAP or IMPDH2-MO. However, the head vessels were dilated and appeared wider compared with the control embryos ( Figure, G to I) . Because the expression of IMPDH2 in the head is less extensive than that in the trunk, the abnormally dilated appearance of head vessels may be caused by localized blockade of angiogenesis. In summary, we established in vivo that treatment of MPA and knockdown of its biological target IMPDH both have antiangiogenic activity in zebrafish. Because the angiogenesis process and IMPDH genes are highly conserved from zebrafish to mammals, together with the other recent independent studies, 8, 9 it should be a reasonable next step to test clinic use of MPA on inhibiting angiogenesis and to develop new drugs targeting IMPDH for antiangiogenesis therapies in humans.
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